Your browser doesn't support javascript.
loading
"Things Have Changed"-Laparoscopic Cytoreduction for Advanced and Recurrent Ovarian Cancer: The Experience of a Referral Center on 108 Patients.
Ceccaroni, Marcello; Roviglione, Giovanni; Bruni, Francesco; Dababou, Susan; Venier, Martina; Zorzi, Carlotta; Salgarello, Matteo; Ruffo, Giacomo; Alongi, Filippo; Gori, Stefania; Driul, Lorenza; Uccella, Stefano; Barra, Fabio.
Afiliação
  • Ceccaroni M; Department of Obstetrics and Gynecology, Gynecologic Oncology and Minimally-Invasive Pelvic Surgery, International School of Surgical Anatomy, IRCCS Sacro Cuore "Don Calabria" Hospital, Negrar, 37024 Verona, Italy.
  • Roviglione G; Department of Obstetrics and Gynecology, Gynecologic Oncology and Minimally-Invasive Pelvic Surgery, International School of Surgical Anatomy, IRCCS Sacro Cuore "Don Calabria" Hospital, Negrar, 37024 Verona, Italy.
  • Bruni F; Department of Obstetrics and Gynecology, Gynecologic Oncology and Minimally-Invasive Pelvic Surgery, International School of Surgical Anatomy, IRCCS Sacro Cuore "Don Calabria" Hospital, Negrar, 37024 Verona, Italy.
  • Dababou S; Department of Obstetrics and Gynecology, AOUI Verona, University of Verona, 37129 Verona, Italy.
  • Venier M; Obstetrics and Gynecology, Department of Medical Area (DAME), University of Udine, 33100 Udine, Italy.
  • Zorzi C; Department of Obstetrics and Gynecology, Gynecologic Oncology and Minimally-Invasive Pelvic Surgery, International School of Surgical Anatomy, IRCCS Sacro Cuore "Don Calabria" Hospital, Negrar, 37024 Verona, Italy.
  • Salgarello M; Department of Nuclear Medicine, IRCCS Sacro Cuore "Don Calabria" Hospital, Negrar, 37024 Verona, Italy.
  • Ruffo G; Department of General Surgery, IRCSS "Sacro Cuore-Don Calabria" Hospital, Negrar di Valpolicella, 37024 Verona, Italy.
  • Alongi F; Department of Advanced Radiation Oncology, IRCCS Sacro Cuore Don Calabria, 37024 Verona, Italy.
  • Gori S; Department of Medical Oncology, IRCCS Sacro Cuore "Don Calabria" Hospital, Negrar, 37024 Verona, Italy.
  • Driul L; Obstetrics and Gynecology, Department of Medical Area (DAME), University of Udine, 33100 Udine, Italy.
  • Uccella S; Department of Obstetrics and Gynecology, AOUI Verona, University of Verona, 37129 Verona, Italy.
  • Barra F; Department of Obstetrics and Gynecology, Gynecologic Oncology and Minimally-Invasive Pelvic Surgery, International School of Surgical Anatomy, IRCCS Sacro Cuore "Don Calabria" Hospital, Negrar, 37024 Verona, Italy.
Cancers (Basel) ; 15(24)2023 Dec 06.
Article em En | MEDLINE | ID: mdl-38136272
ABSTRACT

OBJECTIVE:

To report the feasibility of laparoscopic cytoreduction surgery for primary and recurrent ovarian cancer in a select group of patients.

METHODS:

A retrospective analysis was conducted on a cohort of patients with FIGO stage IIIA-IV advanced ovarian cancer who underwent laparoscopic primary debulking surgery (PDS), interval debulking surgery (IDS), or secondary debulking surgery (SDS) between June 2008 and January 2020. The primary endpoint was achieving optimal cytoreduction, defined as residual tumor less than 1 cm. Secondary endpoints included evaluating surgical complications and long-term survival, assessed at three-month intervals during the initial two years and then every six months.

RESULTS:

This study included a total of 108 patients, among whom, 40 underwent PDS, 44 underwent IDS, and 24 underwent SDS. Optimal cytoreduction rates were found to be 95.0%, 97.7%, and 95.8% for the PDS, ISD, and SDS groups, respectively. Early postoperative complications (<30 days from surgery) occurred in 19.2% of cases, with 7.4% of these cases requiring reintervention. One patient died following postoperative respiratory failure. Late postoperative complications (<30 days from surgery) occurred in 9.3% of cases, and they required surgical reintervention only in one case. After laparoscopic optimal cytoreduction with a median follow-up time of 25 months, the overall recurrence rates were 45.7%, 38.5%, and 39.3% for PDS, ISD, and SDS, respectively. The three-year overall survival rates were 84%, 66%, and 63%, respectively, while the three-year disease-free survival rates were 48%, 51%, and 71%, respectively.

CONCLUSIONS:

Laparoscopic cytoreduction surgery is feasible for advanced ovarian cancer in carefully selected patients, resulting in high rates of optimal cytoreduction, satisfactory peri-operative morbidity, and encouraging survival outcomes. Future studies should focus on establishing standardized selection criteria and conducting well-designed investigations to further refine patient selection and evaluate long-term outcomes.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article